Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.80), $0.42 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $157 million versus the consensus estimate of $130.76 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 EPS of $875.00-$900.00, versus the consensus of $866.50.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary